MTOR and hepatocellular carcinoma: Nevertheless, for patients with a high risk of recurrence (HCC out of the Milan criteria, histological findings such as microvascular invasion or satellitosis), tacrolimus with reduced target levels combined with mTOR inhibitors may be beneficial.